Full-Time

IT Team Leader

Perceptive Discovery

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

No salary listed

London, UK

In Person

On-site at Hammersmith Hospital, London

Category
IT & Security (1)
Required Skills
Microsoft Azure
Agile
Computer Networking
AWS
Hyper-V
VMWare
DevOps

Get referred to Perceptive

See people who can refer or advise you

Requirements
  • In-depth technical knowledge of Networking and Virtualisation technologies (VMware/Hyper-V)
  • Broad understanding of Microsoft 365 services
  • Proficient in backup technologies (Veeam/Acronis)
  • Proficient in Cloud technologies (AWS ideally/Azure)
  • Excellent interpersonal, verbal and written communication skills
  • A flexible attitude with respect to work assignments and new learning
  • Ability to manage a small, established team, delegating effectively, driving standards and motivating, developing and coordinating the work of team members
  • Driven and enthusiastic, able to manage multiple and varied tasks and prioritize own workload with attention to detail
  • Maintains an up-to-date awareness of trends, tools, technology, techniques and processes that affect technology within the Life sciences domain
  • Industry recognised technical certification (e.g. Microsoft/AWS/VMware/CompTIA/Veeam)
  • Proven experience in highly regulated environments (GxP ideally, ISO17025, or similar) or relevant, transferable experience from another domain (e.g., healthcare, financial services, etc.)
  • Previous line management or leadership experience ideally or experience of leading significant project teams
  • Excellent communication and presentation skills
  • Understanding of Agile behaviours or DevOps methodologies
  • English fluency
Responsibilities
  • Ensure team adherence to Service Level Agreements by monitoring metrics against agreed KPIs
  • Ensure all IT services remain operational and available for all aspects of the site
  • Oversee assignments and tasks of team members
  • Create, monitor, and deliver IT projects based on business and site needs
  • Consult with business stakeholders to ensure project success
  • Ensure all project documentation is up-to-date and complete
  • Proactively review the equipment and services supporting the clinical and pre-clinical business to reduce risk rather than address issues
  • Ensure adherence to quality processes and procedures
  • Creation/maintenance of IT processes
  • Manage and track all risks in the risk register with proper follow up actions
  • Monitor and report on site IT expenditure
  • Make capital expenditure recommendations
  • Input to financial forecasting
  • Allocate and prioritize workload across team members
  • Ensure adherence to policies, procedures, and regulatory compliance
  • Foster a culture of ownership, collaboration, and continuous improvement
  • Ensure timesheets are completed every month with adequate level of detail

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Alpha-emitting oncology programs are expanding, and Perceptive targets this fast-growing niche.
  • The January 2026 $15M investment adds two-site At-211 infrastructure in the U.S. and U.K.
  • Exclusive MH3D service-provider status strengthens Perceptive's positioning with radiopharmaceutical sponsors.

What critics are saying

  • CapVest owns Perceptive after the 2025 Calyx acquisition, limiting strategic independence.
  • Ennov bought Calyx Enterprise Technology in February 2024, shrinking Perceptive's software breadth.
  • Perceptive now depends on radiopharmaceutical demand and MH3D execution for α-Sight™ adoption.

What makes Perceptive unique

  • Perceptive Discovery launched α-Sight™ with MH3D on April 15, 2026 for alpha imaging.
  • Perceptive invested $15M on January 8, 2026 to expand radiochemistry and At-211 capabilities.
  • Perceptive combines imaging, radiochemistry, VivoQuant™, and preclinical workflows across oncology and CNS.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.